BPC-157 and TB-500How to Combine Them for Injury Recovery
The combination of BPC-157 and TB-500 — commonly called the Wolverine Stack — is one of the most widely used peptide protocols for injury recovery. The two peptides target different bottlenecks in the healing process: BPC-157 restores blood flow to damaged tissue while TB-500 mobilizes the repair cells that rebuild it.
When tissue is damaged, the body's emergency response chokes microcirculation and traps fibroblasts in place. Unless new capillaries grow and repair cells start moving again, healing stalls. BPC-157 reopens the vascular network; TB-500 directs the cells traveling on it.
This combination is commonly used in the first 4–8 weeks of injury recovery to establish the vascular and cellular foundation that all later healing depends on.
At a Glance
| Compound | Primary Role | Dose | Frequency | Route |
|---|---|---|---|---|
| BPC-157 | Vascular restoration | 500–750 mcg | Daily | SubQ |
| TB-500 | Cell migration & matrix organization | 3–5 mg | 2× weekly | SubQ/IM |
Cycle length: 6–10 weeks (TB-500), 8–12 weeks (BPC-157)
Bottom line: The Wolverine Stack peptides work as a team—BPC-157 builds the vascular roads while TB-500 directs the repair cells traveling on them.
Who This Is For
People with tendon, ligament, or soft tissue injuries who want:
- A simpler protocol focused on the two most critical repair bottlenecks
- Clear structure without managing five compounds
- A foundation that can be expanded if needed
This stack addresses vascular access and cellular mobility—the layers most injuries need first. For more complex or chronic injuries, the 5-compound protocol adds energy, collagen quality, and inflammation control.
Why These Two Together
After injury, the body's first reaction is containment: vessels constrict, platelets form clots, and inflammatory cells flood the site. That emergency response stops bleeding but also chokes micro-circulation, leaving the region hypoxic and energy-starved. Unless new capillaries grow and fibroblasts start moving again, healing stalls in the inflammatory phase.
This is the "half-healed" state many people know too well:
- Pain that waxes and wanes
- Stiffness that never fully resolves
- Tissue that feels both tight and weak
- Morning mobility that takes 20+ minutes to return
How They Work
| Compound | Key Mechanisms | What You Notice |
|---|---|---|
| BPC-157 | VEGF upregulation (vascular endothelial growth factor — the signal that builds new blood vessels), eNOS activation (endothelial nitric oxide synthase — enzyme that produces nitric oxide for blood flow), FAK-paxillin cascade (focal adhesion kinase pathway — how cells anchor and migrate during repair), anti-cytokine modulation (lowers TNF-α/IL-6), neuro-angiogenic signaling | Warmth returns; swelling becomes productive; scar forms in organized lines; sensory recovery around injury site |
| TB-500 | Actin polymerization (the process by which cells build their internal scaffolding to move and divide), MMP modulation (matrix metalloproteinases — enzymes that clear damaged tissue so new tissue can form), M2 macrophage polarization (shifting immune cells from inflammatory mode to repair mode), anti-fibrotic signaling | Tissue softens; fascia glides; old adhesions remodel; scar tissue stays flexible |
BPC-157's neuro-angiogenic signaling promotes peripheral nerve sprouting alongside new blood vessels—this is why sensory "dead zones" around injuries often recover faster with this peptide. The anti-cytokine effect (reducing TNF-α and IL-6) calms inflammation without suppressing the repair process, unlike NSAIDs which can impair collagen quality.
Synergy
| Interaction | Outcome |
|---|---|
| BPC-157 × TB-500 | Perfusion + migration → organized tissue reconstruction |
| Combined NO + M2 polarization | Rapid inflammation resolution with simultaneous tissue regeneration |
Together they shift tissue from M1 macrophages (the first-responder inflammatory immune cells) to M2 macrophages (the repair-phase immune cells that rebuild tissue) without the collateral effects of NSAIDs or steroids.
Dosing
| Compound | Dose | Frequency | Route | Notes |
|---|---|---|---|---|
| BPC-157 | 500–750 mcg | Daily | SubQ (near injury or systemic) | Peri-lesional preferred |
| TB-500 | 3–5 mg | 2× weekly | SubQ or IM | ≥72 hours between doses |
Cycle length: 6–10 weeks (TB-500), 8–12 weeks (BPC-157)
Weight-Based Guidance
- BPC-157: ~6–8 mcg/kg daily
- TB-500: ~0.04–0.06 mg/kg per dose
Weekly Schedule (Example)
| Compound | Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|---|
| BPC-157 | 500 mcg | 500 mcg | 500 mcg | 500 mcg | 500 mcg | 500 mcg | 500 mcg |
| TB-500 | 4 mg | — | — | 4 mg | — | — | — |
Adjust based on your schedule. Consistency matters more than specific days.
Timeline: What to Expect
Days 3–7
- What's happening — Re-perfusion of micro-vasculature
- What you notice — Less sharp pain; gentle warmth at site
- Side effects — Mild local reactions; TB-500 may cause brief lethargy
Weeks 1–2
- What's happening — Fibroblast migration; collagen matrix forming
- What you notice — Less "locked" feeling; morning stiffness fades faster
- Challenge — Stay patient—structural changes take time
Weeks 2–4
- What's happening — Early remodeling; collagen organization begins
- What you notice — Tissue feels pliable, not stiff; load tolerance rising
- Decision point — If progress clear, continue; if stalled, consider adding compounds
Weeks 4–8
- What's happening — Consolidation and maturation
- What you notice — Strength returning; tissue behaves more like original
- Maintenance — TB-500 can taper to weekly after week 6 if stable
Most people notice reduced pain and improved warmth within the first 1–2 weeks. Functional improvements (load tolerance, mobility) typically develop over weeks 3–4.
Supporting Factors
| Component | Target | Why |
|---|---|---|
| Vitamin C | 500 mg AM/PM | Collagen cross-linking cofactor |
| Collagen peptides | 10 g daily | Raw material |
| Glycine | 3 g daily | Rate-limiting collagen amino acid |
| Movement | Gentle ROM within pain-free limits | Directional stress organizes collagen |
| Sleep | 7–9 hours | Angiogenesis hormones peak during deep sleep |
Movement matters: Static rest delays organized healing—the new collagen needs directional stress signals.
When Progress Stalls
| Step | Action |
|---|---|
| 1 | Check protein, sleep, hydration. Under-eating stalls repair. |
| 2 | Verify injection technique and storage conditions. |
| 3 | If tissue is warm but energy feels low → Add NAD+ |
| 4 | If collagen quality seems poor (mushy, not elastic) → Add GHK-Cu |
| 5 | If inflammation persists (swelling after activity) → Add KPV |
| 6 | For all three bottlenecks → Move to 5-compound protocol |
Managing Side Effects
| Issue | Primary Mitigation | Secondary Options |
|---|---|---|
| BPC-157 local warmth | Normal; no action needed | Rotate sites if persistent |
| TB-500 lethargy (12–24 hrs) | Hydrate; rest day after injection | Split into smaller doses |
| Injection site reactions | Rotate sites; check technique | Warm peptide before injection |
Contraindications
Do not use if:
- Active cancer or malignancy within 2 years (both peptides promote angiogenesis)
- Pregnancy or breastfeeding
- Proliferative retinopathy
- Surgery planned or recent (<2 weeks)
Use with medical supervision if:
- Concurrent corticosteroid use (steroids oppose tissue repair mechanisms)
- Severe cardiovascular disease
- Active autoimmune conditions
- Therapeutic anticoagulation
Sports compliance: TB-500 is prohibited by WADA/USADA.
What Comes Next
After 6–8 weeks, assess:
Complete: If markers are met (pain ≤2/10, ROM ≥80%, no edema after activity, tissue warm and supple), taper off. Many clinicians recommend 2–4 week taper rather than abrupt stop.
Extend: If progress is good but incomplete, continue for another 4 weeks.
Upgrade: If specific bottlenecks persist, move to the 5-compound protocol or add individual compounds:
- Energy issues → NAD+
- Collagen quality → GHK-Cu
- Inflammation → KPV
For chronic injuries with sleep disruption, see Tesamorelin for Injury Recovery. For neuropathic symptoms, see ARA-290 for Nerve Pain.
Storage and Handling
- Reconstitute with bacteriostatic water under clean technique (see Reconstitution Guide for step-by-step instructions)
- Refrigerate at 2–8°C after reconstitution; protect from light
- Beyond-use: 2–4 weeks refrigerated
- BPC-157 and TB-500 can be co-injected (pH compatible)
FAQ
Can I combine BPC-157 and TB-500 in one syringe?
Yes, they're pH compatible. Many clinicians co-inject without issues. If you're unsure about stability, use separate syringes. Avoid mixing either with acidic peptides like NAD+.
What if I'm still in a brace or boot?
Start with systemic injections (abdomen/thigh). Once cleared to move, shift BPC-157 closer to the injury site. Immobilization doesn't prevent peptide benefit, but collagen alignment will be less organized without directional stress.
Should I stop physical therapy?
No. These peptides support PT—they restore blood flow, which makes rehab exercises more effective. The peptides provide the infrastructure; PT provides the directional stress signals for organized collagen.
How long until I feel something?
Most people notice reduced pain and improved warmth within the first 1–2 weeks. Functional improvements (load tolerance, mobility) typically develop over weeks 3–4. If you feel nothing by week 3, reassess injection technique, storage conditions, or discuss dosing with your clinician.
Is local injection really better than systemic?
For tendon/ligament injuries, local injection (1–2 cm from the injury site) typically produces faster, more targeted results. However, systemic injection still works—both peptides reach target tissues through circulation. If local injection is impractical or uncomfortable, systemic is a valid approach.
Can I take NSAIDs while using these peptides?
Avoid if possible. NSAIDs suppress the inflammatory phase of healing, which can interfere with the signals these peptides are trying to restore. If you must use NSAIDs for acute pain, use the lowest effective dose for the shortest duration.
What about corticosteroid injections?
Corticosteroids and repair peptides work against each other. Steroids suppress fibroblast proliferation and angiogenesis—exactly what BPC-157 and TB-500 are trying to promote. If you've had a recent steroid injection, wait 2–4 weeks before starting peptide therapy.
How do I know if the peptides are working?
Early signs (week 1–2): Warmth returning to the area, reduced sharp pain, less morning stiffness.
Later signs (week 3–4): Improved pliability, better tolerance of gentle loading, ROM improvements, less reactivity after activity.
What's the difference between TB-500 and TB-4?
TB-500 is supposed to be thymosin β4 fragment 17–23—a small, 7-amino-acid active fragment (~800 Da molecular weight).
TB-4 is the full-length 43-amino-acid thymosin β4 protein (~4,900 Da molecular weight).
The problem: Most vendors selling "TB-500" are actually selling full TB-4. The fragment is harder to synthesize and less commercially available. Both have tissue repair activity, but they're not the same compound.
How do I know if I have real TB-500 or TB-4?
Check the Certificate of Analysis (COA) or third-party lab report:
| What to Look For | TB-500 (Fragment) | TB-4 (Full Protein) |
|---|---|---|
| Molecular weight | ~800 Da | ~4,900 Da |
| Amino acid count | 7 amino acids | 43 amino acids |
| Sequence | LKKTETQ | Full sequence starting with SDKPDM... |
| Mass spec peak | ~800 m/z | ~4,900 m/z |
If the COA shows molecular weight around 4,900 Da or lists 43 amino acids, you have TB-4, not TB-500—regardless of what the label says.
Does it matter? Both work for tissue repair. TB-4 is the parent molecule; the fragment contains the active region. Most clinical and research literature uses TB-4. The main issue is knowing what you're actually using for dosing purposes.
Should I continue after the injury feels healed?
Many clinicians recommend a 2–4 week taper rather than abrupt cessation. During taper, reduce TB-500 frequency first (once weekly), then BPC-157 (every other day). This allows collagen remodeling to consolidate.
What if pain increases during the first week?
Mild increases in awareness or dull aching can occur as blood flow returns—this is the "warming up" effect. However, if pain increases significantly (>4/10) or changes character (becomes sharp, burning, or shooting), pause and consult your clinician.
Can I use these for chronic injuries (6+ months old)?
Yes, but expectations should be realistic. Chronic injuries often have multiple bottlenecks beyond vascular access. BPC-157 + TB-500 address the foundational layers. Complete chronic injury resolution often requires the 5-compound protocol or add-on modules.
Are there long-term risks?
Human long-term safety data is limited. The primary theoretical concern is promoting angiogenesis in contexts where it's harmful (occult malignancy, proliferative retinopathy). For healthy individuals without these conditions, no significant long-term adverse effects have been identified. Most practitioners use defined cycles rather than indefinite use.
Related Topics
- 5-Compound Protocol — Complete protocol with NAD+, GHK-Cu, KPV
- Tesamorelin Guide — includes GH timing and injury recovery section
- ARA-290 Guide — includes nerve pain and injury recovery section
- SS-31 Guide — includes mitochondrial stability section
- Complete BPC-157 Guide — Deep dive on BPC-157
- NAD+ Guide — Cellular energy
References
- BPC-157 review: PMC8275860
- TB-500 dermal repair: PubMed 12581423
- TB-500 fragment context: PMC7822313
Educational content only. Some compounds discussed are FDA-approved medications; others are research peptides without FDA approval — not due to safety concerns, but because unpatentable compounds cannot justify the required trial investment. Work with a qualified healthcare provider before using any protocol.
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.